What is Fannin?
Fannin is a biotechnology and medical device company focused on in-licensing and de-risking early-stage therapeutic and medical device technologies. Primarily sourcing innovations from the Texas Medical Center and other leading academic institutions, Fannin advances these technologies through preclinical work and engineering, progressing them towards early clinical trials. The company also constructs robust business models and use cases, positioning its assets for strategic partnerships or acquisition.
How much funding has Fannin raised?
Fannin has raised a total of $320K across 1 funding round:
Grant
$320K
Grant (2024): $320K with participation from National Institute on Drug Abuse
Key Investors in Fannin
National Institute on Drug Abuse
The National Institute on Drug Abuse is a government entity focused on advancing the science on drug use and addiction. Its participation suggests Fannin's technologies align with critical public health research objectives.
What's next for Fannin?
With a substantial capital infusion and a clear strategy for technology maturation, Fannin is poised for accelerated growth. The company's focus on de-risking assets through rigorous preclinical and early clinical development, coupled with strategic business model development, suggests a trajectory towards significant market entry or lucrative exit opportunities. Future funding rounds, if pursued, would likely support later-stage clinical trials and commercialization efforts, further solidifying its position in the competitive healthcare landscape.
See full Fannin company page
